Lv3
230 积分 2021-04-25 加入
OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
1天前
待确认
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
3天前
已完结
Tivanisiran, a novel siRNA for the treatment of dry eye disease
8天前
已完结
Recent Progress of Small Interfering RNA Delivery on the Market and Clinical Stage
8天前
已完结
An open-label, uncontrolled, 8-week clinical trial of barnidipine hydrochloride, a once-daily calcium channel blocker, in Korean patients with essential hypertension
11天前
已完结
Angiotensin Peptides as AT2 Receptor Agonists
11天前
已完结
Medulloblastoma drugs in development: Current leads, trials and drawbacks
12天前
已完结
Once-daily sustained-release matrix tablets of nicorandil: Formulation and in vitro evaluation
15天前
已完结
Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma
15天前
已完结
Chemotherapy‐induced thrombocytopenia: modern diagnosis and treatment
15天前
已完结
皖公网安备34019202002308
